Document Actions
AIMM Therapeutics B.V.
Business focus: Development of fully human antibodies for prophylaxis and therapy of infectious diseases.
|
AIMM Therapeutics B.V. Employees in Amsterdam: 5 |
Company Profile
AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.
Science and Technologies or Services
The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.
Alliances
- AMC-Amsterdam;
- UMCU-Utrecht;
- NVI-Bilthoven.
Keywords
- Human antibodies;
- Vaccines.